One Biosciences receives BOOST grant from Paris-Saclay Cancer Cluster

What's the deal? One Biosciences, a Paris techbio firm, has secured a BOOST grant from the Paris-Saclay Cancer Cluster (PSCC).

The funding will help it develop the first single-cell assay for antibody-drug conjugate (ADC) therapies in oncology.

The project pairs One Biosciences' AI-powered single-cell profiling with the ADC expertise of clinical-stage biotech Adcytherix. Together they will analyse tumour samples to find cellular signatures tied to treatment response.

Why now? ADCs are growing fast, and that growth is driving demand for sharper biomarker strategies.

Single-cell profiling captures tumour complexity at cellular resolution, which could improve patient selection and shape next-generation ADCs.

"This grant is an important milestone for One Biosciences and for the broader adoption of single-cell technologies in oncology drug development," said chief executive officer Hedi Ben Brahim.

What could go wrong? The work is early-stage and aimed at laying the foundation for future companion diagnostics, not a finished product.

Success depends on linking cellular signatures to real treatment outcomes — a scientific bet that may not pay off.

The signal: Now at breakout stage, One Biosciences is leaning on its "discovery engine" of single-cell technologies to push deeper into difficult-to-treat diseases. Backed by specialist life-sciences funds Redmile GroupDealroom has a profile for this one. Try Dealroom →, Sofinnova Partners, and Blast, the company is betting that clinical-grade single-cell profiling can become a standard tool in the fast-growing ADC market.

Read more: Business Wire

Image credit: AI-generated image (Gemini)